NovoCure (NASDAQ:NVCR) Insider Sells $14,641.00 in Stock

NovoCure Limited (NASDAQ:NVCR) insider Michal Nath Puri sold 1,100 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $13.31, for a total transaction of $14,641.00. Following the completion of the sale, the insider owned 201,322 shares of the company’s stock, valued at $2,679,595.82. The trade was a 0.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

NovoCure Stock Performance

NASDAQ:NVCR opened at $13.04 on Friday. The firm has a market capitalization of $1.48 billion, a PE ratio of -10.69 and a beta of 0.71. NovoCure Limited has a 1 year low of $9.82 and a 1 year high of $21.55. The company has a current ratio of 2.90, a quick ratio of 1.50 and a debt-to-equity ratio of 0.70. The firm’s fifty day simple moving average is $12.74 and its 200 day simple moving average is $12.72.

NovoCure (NASDAQ:NVCR) last released its earnings results on Thursday, February 26th. The medical equipment provider reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.19. The firm had revenue of $174.35 million during the quarter, compared to analyst estimates of $174.40 million. NovoCure had a negative net margin of 20.79% and a negative return on equity of 39.11%. The business’s revenue was up 8.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.61) EPS. On average, sell-side analysts anticipate that NovoCure Limited will post -1.3 EPS for the current year.

Key NovoCure News

Here are the key news stories impacting NovoCure this week:

• Positive Sentiment: Q4 results beat EPS expectations (reported ($0.22) vs. ($0.41) est.) and revenue rose ~8.2% year‑over‑year — a fundamental positive that supports a recovery narrative and gives analysts a basis for higher targets. MarketBeat NVCR coverage
• Positive Sentiment: Some sell‑side firms remain constructive (e.g., HC Wainwright raised its target and several analysts maintain Buy ratings), providing upside scenarios if clinical/commercial momentum continues. Analyst notes (MarketBeat)
• Neutral Sentiment: Brokerage consensus is an overall “Hold,” signaling limited near‑term conviction for a sustained re‑rating despite divergent analyst targets. NovoCure receives average “Hold” rating
• Neutral Sentiment: High institutional ownership (~84.6%) concentrates share control; that reduces free float but means large insider blocks can have outsized market impact when sold. Institutional holdings (MarketBeat)
• Neutral Sentiment: Minor individual insider sale by Michal Nath Puri (1,100 shares) is immaterial alone but contributes to the overall recent selling narrative. InsiderTrades alert
• Negative Sentiment: Chairman William F. Doyle sold a large block (71,887 shares, ≈$933k), trimming his stake by ~18% — a substantial single insider sale that markets typically read as negative signaling. SEC filing: Doyle sale
• Negative Sentiment: Multiple senior executives (COO Mukund Paravasthu, CEO Frank Leonard, CFO Christoph Brackmann and others) executed notable sales in the same window — an aggregated pattern that likely amplified selling pressure and contributed to intraday weakness. SEC filings: Executive sales summary

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NVCR. Morgan Stanley raised its holdings in shares of NovoCure by 453.4% in the 4th quarter. Morgan Stanley now owns 5,069,895 shares of the medical equipment provider’s stock worth $65,554,000 after buying an additional 4,153,741 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in NovoCure by 25.0% in the 2nd quarter. Soleus Capital Management L.P. now owns 6,904,302 shares of the medical equipment provider’s stock valued at $122,897,000 after buying an additional 1,382,888 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its position in NovoCure by 1,093.2% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,223,755 shares of the medical equipment provider’s stock valued at $15,823,000 after acquiring an additional 1,121,192 shares during the period. American Century Companies Inc. grew its position in NovoCure by 1,354.7% in the second quarter. American Century Companies Inc. now owns 1,029,874 shares of the medical equipment provider’s stock valued at $18,332,000 after acquiring an additional 959,079 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in NovoCure during the fourth quarter worth $11,991,000. Institutional investors own 84.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVCR. HC Wainwright upped their price target on NovoCure from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Evercore set a $20.00 target price on shares of NovoCure in a research note on Monday, January 5th. Weiss Ratings restated a “sell (e+)” rating on shares of NovoCure in a research report on Thursday, January 22nd. Finally, Wedbush reaffirmed a “neutral” rating and set a $18.00 price objective on shares of NovoCure in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, NovoCure presently has an average rating of “Hold” and an average price target of $26.93.

About NovoCure

NovoCure is a global oncology company pioneering Tumor Treating Fields (TTFields), a novel anti-mitotic therapy for solid tumors. The company’s non-invasive treatment platforms deliver low-intensity, alternating electric fields designed to disrupt cancer cell division. NovoCure’s approach offers an alternative modality to complement existing therapies in oncology, with a focus on hard-to-treat malignancies.

Founded in 2000 and headquartered in Haifa, Israel, NovoCure maintains a second operational center in Portsmouth, New Hampshire.